Search research articles
Contact Us
Filters
Showing results (71-80 of 80) with videos related to
Page
of 8
Sort By:
You have reached the last page of results.
This site can display upto 80 results.
Journal of the American Geriatrics Society
|
August 28, 2018
Functional Decline and Resilience in Older Women Receiving Adjuvant Chemotherapy for Breast Cancer
Arti Hurria, Enrique Soto-Perez-de-Celis, Jacob B Allred, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 2, 2009
Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma
Martha Q Lacy, Suzanne R Hayman, Morie A Gertz, et al.
Leukemia
|
September 10, 2010
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)
M Q Lacy, S R Hayman, M A Gertz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 19, 2023
Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250)
Matthew Ingham, Jacob B Allred, Li Chen, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]
|
August 12, 2020
Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination
Ryan M Carr, Narjust Duma, Angela L McCleary-Wheeler, et al.
Blood
|
June 22, 2011
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease
Martha Q Lacy, Jacob B Allred, Morie A Gertz, et al.
Frontiers in Immunology
|
November 29, 2023
A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses
Katherine E R Smith, Kah-Whye Peng, Jose S Pulido, et al.
Nature Communications
|
October 15, 2020
Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients
Matthew S Block, Allan B Dietz, Michael P Gustafson, et al.
Annals of Surgical Oncology
|
May 2, 2022
Oncologic Outcomes of Multi-Institutional Minimally Invasive Inguinal Lymph Node Dissection for Melanoma Compared with Open Inguinal Dissection in the Second Multicenter Selective Lymphadenectomy Trial (MSLT-II)
James W Jakub, Michael Lowe, J Harrison Howard, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]
|
December 3, 2019
Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer
Angela L McCleary-Wheeler, Ryan M Carr, Shanique R Palmer, et al.
Page
of 8
Search research articles
Search
Showing results (71-80 of 80) with videos related to
Sort By:
Page
of 8
You have reached the last page of results.
This site can display upto 80 results.
Journal of the American Geriatrics Society
|
August 28, 2018
Functional Decline and Resilience in Older Women Receiving Adjuvant Chemotherapy for Breast Cancer
Arti Hurria, Enrique Soto-Perez-de-Celis, Jacob B Allred, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 2, 2009
Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma
Martha Q Lacy, Suzanne R Hayman, Morie A Gertz, et al.
Leukemia
|
September 10, 2010
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)
M Q Lacy, S R Hayman, M A Gertz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 19, 2023
Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250)
Matthew Ingham, Jacob B Allred, Li Chen, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]
|
August 12, 2020
Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination
Ryan M Carr, Narjust Duma, Angela L McCleary-Wheeler, et al.
Blood
|
June 22, 2011
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease
Martha Q Lacy, Jacob B Allred, Morie A Gertz, et al.
Frontiers in Immunology
|
November 29, 2023
A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses
Katherine E R Smith, Kah-Whye Peng, Jose S Pulido, et al.
Nature Communications
|
October 15, 2020
Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients
Matthew S Block, Allan B Dietz, Michael P Gustafson, et al.
Annals of Surgical Oncology
|
May 2, 2022
Oncologic Outcomes of Multi-Institutional Minimally Invasive Inguinal Lymph Node Dissection for Melanoma Compared with Open Inguinal Dissection in the Second Multicenter Selective Lymphadenectomy Trial (MSLT-II)
James W Jakub, Michael Lowe, J Harrison Howard, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]
|
December 3, 2019
Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer
Angela L McCleary-Wheeler, Ryan M Carr, Shanique R Palmer, et al.
Page
of 8